Skip to main content

US ClosedU.S. Closed

Healthcare · Biotechnology

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment.

52W Range

63rdpctl

Volume

0.49×avg

Market Cap

1.44BUSD

P/E Ratio

-25.8TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Aktis Oncology, Inc.

AKTSNASDAQ Global Select·USD·Closed

Aktis Oncology, Inc.

AKTSNASDAQ·USD·Closed

$27.05

+1.50%

$27.05

+$0.40 (1.50%)

52W Range

63rdpctl

Volume

0.49×avg

Mkt Cap

1.44BUSD

P/E

-25.8TTM

Div Yield

–ann

AKTS: Aktis Oncology, Inc. Stock Analysis | finqOS